Evaluating biomarkers in melanoma

Frontiers in Oncology

Volumn 4, Issue JAN, 2015, Pages

  Karagiannis, Panagiotis ^a,b   Fittall, Matthew ^a,b   Karagiannis, Sophia N ^a,b  

^a KING'S COLLEGE LONDON   (United Kingdom)

^b GUY'S AND ST THOMAS' NHS FOUNDATION TRUST   (United Kingdom)

Author keywords

Antibodies; Biomarkers; Cancer; Humoral immunity; Immune response; Inflammation; Melanoma; Prognosis

Indexed keywords

CELL ADHESION MOLECULE; CYCLOOXYGENASE 2; DACARBAZINE; GALECTIN 3; GLYCOPROTEIN GP 39; INTERLEUKIN 8; IPILIMUMAB; LACTATE DEHYDROGENASE; MATRIX METALLOPROTEINASE; MONOPHENOL MONOOXYGENASE; OSTEOPONTIN; PROTEIN S 100; PROTEOCHONDROITIN SULFATE; TEMOZOLOMIDE; VASCULOTROPIN; VEMURAFENIB;

ARTICLE; CANCER GROWTH; CANCER INCIDENCE; CANCER PROGNOSIS; CANCER RECURRENCE; CANCER STAGING; CELL ADHESION; COMBINATION CHEMOTHERAPY; CUTANEOUS MELANOMA; CYTOTOXICITY; GENE MUTATION; HUMAN; IMMUNE RESPONSE; IMMUNOTHERAPY; KERATOACANTHOMA; MALIGNANT LENTIGO; MITOSIS RATE; MOLECULARLY TARGETED THERAPY; OUTCOME ASSESSMENT; PATIENT MONITORING; PROGRESSION FREE SURVIVAL; REGIONAL PERFUSION; RISK ASSESSMENT; SIGNAL TRANSDUCTION; SQUAMOUS CELL CARCINOMA; ULCER; VALIDATION PROCESS;

EID: 84935088961     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00383     Document Type: Article

References (130)

1. Giblin AV, Thomas JM. Incidence, mortality and survival in cutaneous melanoma. J Plast Reconstr Aesthet Surg (2007) 60(1):32-40. doi:10.1016/j.bjps.2006.05.008.
2. CRUK. Melanoma Statistics and Outlook. (2011). Available from: http://www.cancerhelp.org.uk/type/melanoma/treatment/melanoma-statistics-and-outlook.
3. Verdecchia P, Angeli F, Repaci S, Mazzotta G, Gentile G, Reboldi G. Comparative assessment of angiotensin receptor blockers in different clinical settings. Vasc Health Risk Manag (2009) 5:939-48. doi:10.2147/VHRM.S7263.
4. Balch CM, Gershenwald JE, Soong SJ, Thompson JF, Atkins MB, Byrd DR, et al. Final version of 2009 AJCC melanoma staging and classification. J Clin Oncol (2009) 27(36):6199-206. doi:10.1200/JCO.2009.23.4799.
5. Balch CM, Balch GC, Sharma RR. Identifying early melanomas at higher risk for metastases. J Clin Oncol (2012) 30(13):1406-7. doi:10.1200/JCO.2011.40.6983.
6. Green AC, Baade P, Coory M, Aitken JF, Smithers M. Population-based 20-year survival among people diagnosed with thin melanomas in Queensland, Australia. J Clin Oncol (2012) 30(13):1462-7. doi:10.1200/JCO.2011.38.8561.
7. Chapman PB, Hauschild A, Robert C, Haanen JB, Ascierto P, Larkin J, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med (2011) 364(26):2507-16. doi:10.1056/NEJMoa1103782.
8. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med (2010) 363(8):711-23. doi:10.1056/NEJMoa1003466.
9. Hodi FS, Oble DA, Drappatz J, Velazquez EF, Ramaiya N, Ramakrishna N, et al. CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS. Nat Clin Pract Oncol (2008) 5(9):557-61. doi:10.1038/ncponc1183.
10. Thompson JF, Scolyer RA, Kefford RF. Cutaneous melanoma. Lancet (2005) 365(9460):687-701. doi:10.1016/S0140-6736(05)17951-3.
11. Marsden JR, Newton-Bishop JA, Burrows L, Cook M, Corrie PG, Cox NH, et al. Revised U.K. guidelines for the management of cutaneous melanoma 2010. Br J Dermatol (2010) 163(2):238-56. doi:10.1111/j.1365-2133.2010.09883.x.
12. Morton DL, Thompson JF, Cochran AJ, Mozzillo N, ElashoffR, Essner R, et al. Sentinel-node biopsy or nodal observation in melanoma. N Engl J Med (2006) 355(13):1307-17. doi:10.1056/NEJMoa060992.
13. Burmeister BH, Henderson MA, Ainslie J, Fisher R, Di Iulio J, Smithers BM, et al. Adjuvant radiotherapy versus observation alone for patients at risk of lymph-node field relapse after therapeutic lymphadenectomy for melanoma: a randomised trial. Lancet Oncol (2012) 13(6):589-97. doi:10.1016/S1470-2045(12)70138-9.
14. Dummer R, Hauschild A, Guggenheim M, Keilholz U, Pentheroudakis G, Group EGW. Cutaneous melanoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol (2012) 23(Suppl 7):vii86-91. doi:10.1093/annonc/mds229.
15. Petrella T, Quirt I, Verma S, Haynes AE, Charette M, Bak K, et al. Single-agent interleukin-2 in the treatment of metastatic melanoma: a systematic review. Cancer Treat Rev (2007) 33(5):484-96. doi:10.1016/j.ctrv.2007.04.003.
16. Davies H, Bignell GR, Cox C, Stephens P, Edkins S, Clegg S, et al. Mutations of the BRAF gene in human cancer. Nature (2002) 417(6892):949-54. doi:10.1038/nature00766.
17. Long GV, Menzies AM, Nagrial AM, Haydu LE, Hamilton AL, Mann GJ, et al. Prognostic and clinicopathologic associations of oncogenic BRAF in metastatic melanoma. J Clin Oncol (2011) 29(10):1239-46. doi:10.1200/JCO.2010.32.4327.
18. Flaherty KT, Infante JR, Daud A, Gonzalez R, Kefford RF, Sosman J, et al. Combined BRAF and MEK inhibition in melanoma with BRAF V600 mutations. N Engl J Med (2012) 367(18):1694-703. doi:10.1056/NEJMoa1210093.
19. Flaherty KT, Robert C, Hersey P, Nathan P, Garbe C, Milhem M, et al. Improved survival with MEK inhibition in BRAF-mutated melanoma. N Engl J Med (2012) 367(2):107-14. doi:10.1056/NEJMoa1203421.
20. Tsai J, Lee JT, Wang W, Zhang J, Cho H, Mamo S, et al. Discovery of a selective inhibitor of oncogenic B-Raf kinase with potent antimelanoma activity. Proc Natl Acad Sci USA (2008) 105(8):3041-6. doi:10.1073/pnas.0711741105.
21. McArthur GA, Chapman PB, Robert C, Larkin J, Haanen JB, Dummer R, et al. Safety and efficacy of vemurafenib in BRAF(V600E) and BRAF(V600K) mutation-positive melanoma (BRIM-3): extended follow-up of a phase 3, randomised, open-label study. Lancet Oncol (2014) 15(3):323-32. doi:10.1016/S1470-2045(14)70012-9.
22. Khattak M, Fisher R, Turajlic S, Larkin J. Targeted therapy and immunotherapy in advanced melanoma: an evolving paradigm. Ther Adv Med Oncol (2013) 5(2):105-18. doi:10.1177/1758834012466280.
23. Oberholzer PA, Kee D, Dziunycz P, Sucker A, Kamsukom N, Jones R, et al. RAS mutations are associated with the development of cutaneous squamous cell tumors in patients treated with RAF inhibitors. J Clin Oncol (2012) 30(3):316-21. doi:10.1200/JCO.2011.36.7680.
24. Su F, Viros A, Milagre C, Trunzer K, Bollag G, Spleiss O, et al. RAS mutations in cutaneous squamous-cell carcinomas in patients treated with BRAF inhibitors. N Engl J Med (2012) 366(3):207-15. doi:10.1056/NEJMoa1105358.
25. Zimmer L, Hillen U, Livingstone E, Lacouture ME, Busam K, Carvajal RD, et al. Atypical melanocytic proliferations and new primary melanomas in patients with advanced melanoma undergoing selective BRAF inhibition. J Clin Oncol (2012) 30(19):2375-83. doi:10.1200/JCO.2011.41.1660.
26. Long GV, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, et al. Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma. N Engl J Med (2014) 371(20):1877-88. doi:10.1056/NEJMoa1406037.
27. Larkin J, Ascierto PA, Dreno B, Atkinson V, Liszkay G, Maio M, et al. Combined vemurafenib and cobimetinib in BRAF-mutated melanoma. N Engl J Med (2014) 371(20):1867-76. doi:10.1056/NEJMoa1408868.
28. Eggermont AM, Suciu S, Testori A, Santinami M, Kruit WH, Marsden J, et al. Long-term results of the randomized phase III trial EORTC 18991 of adjuvant therapy with pegylated interferon alfa-2b versus observation in resected stage III melanoma. J Clin Oncol (2012) 30(31):3810-8. doi:10.1200/JCO.2011.41.3799.
29. Mocellin S, Pasquali S, Rossi CR, Nitti D. Interferon alpha adjuvant therapy in patients with high-risk melanoma: a systematic review and meta-analysis. J Natl Cancer Inst (2010) 102(7):493-501. doi:10.1093/jnci/djq009.
30. Robert C, Schadendorf D, Messina M, Hodi FS, O'Day S; Investigators MDX. Efficacy and safety of retreatment with ipilimumab in patients with pretreated advanced melanoma who progressed after initially achieving disease control. Clin Cancer Res (2013) 19(8):2232-9. doi:10.1158/1078-0432.CCR-12-3080.
31. Robert C, Thomas L, Bondarenko I, O'Day S, Weber J, Garbe C, et al. Ipilimumab plus dacarbazine for previously untreated metastatic melanoma. N Engl J Med (2011) 364(26):2517-26. doi:10.1056/NEJMoa1104621.
32. McArthur GA, Ribas A. Targeting oncogenic drivers and the immune system in melanoma. J Clin Oncol (2013) 31(4):499-506. doi:10.1200/JCO.2012.45.5568.
33. Malas S, Harrasser M, Lacy KE, Karagiannis SN. Antibody therapies for melanoma: new and emerging opportunities to activate immunity (Review). Oncol Rep (2014) 32(3):875-86. doi:10.3892/or.2014.3275.
34. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF, et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med (2012) 366(26):2443-54. doi:10.1056/NEJMoa1200690.
35. Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med (2013) 369(2):122-33. doi:10.1056/NEJMoa1302369.
36. Hamid O, Robert C, Daud A, Hodi FS, Hwu WJ, Kefford R, et al. Safety and tumor responses with lambrolizumab (anti-PD-1) in melanoma. N Engl J Med (2013) 369(2):134-44. doi:10.1056/NEJMoa1305133.
37. Robert C, Ribas A, Wolchok JD, Hodi FS, Hamid O, Kefford R, et al. Anti-programmed-death-receptor-1 treatment with pembrolizumab in ipilimumab-refractory advanced melanoma: a randomised dose-comparison cohort of a phase 1 trial. Lancet (2014) 384(9948):1109-17. doi:10.1016/S0140-6736(14)60958-2.
38. Poole RM. Pembrolizumab: first global approval. Drugs (2014) 74(16):1973-81. doi:10.1007/s40265-014-0314-5.
39. Ilieva KM, Correa I, Josephs DH, Karagiannis P, Egbuniwe IU, Cafferkey MJ, et al. Effects of BRAF mutations and BRAF inhibition on immune responses to melanoma. Mol Cancer Ther (2014) 13(12):2769-83. doi:10.1158/1535-7163.MCT-14-0290.
40. Yap TA, Sandhu SK, Workman P, de Bono JS. Envisioning the future of early anticancer drug development. Nat Rev Cancer (2010) 10(7):514-23. doi:10.1038/nrc2870.
41. Egberts F, KotthoffEM, Gerdes S, Egberts JH, Weichenthal M, Hauschild A. Comparative study of YKL-40, S-100B and LDH as monitoring tools for Stage IV melanoma. Eur J Cancer (2012) 48(5):695-702. doi:10.1016/j.ejca.2011.08.007.
42. Quaglino P, Osella-Abate S, Cappello N, Ortoncelli M, Nardo T, Fierro MT, et al. Prognostic relevance of baseline and sequential peripheral blood tyrosinase expression in 200 consecutive advanced metastatic melanoma patients. Melanoma Res (2007) 17(2):75-82. doi:10.1097/CMR.0b013e328054c667.
43. Visus C, Andres R, Mayordomo JI, Martinez-Lorenzo MJ, Murillo L, Saez-Gutierrez B, et al. Prognostic role of circulating melanoma cells detected by reverse transcriptase-polymerase chain reaction for tyrosinase mRNA in patients with melanoma. Melanoma Res (2007) 17(2):83-9. doi:10.1097/CMR.0b013e3280a60878.
44. Samija I, Lukac J, Maric-Brozic J, Buljan M, Alajbeg I, Kovacevic D, et al. Prognostic value of microphthalmia-associated transcription factor and tyrosinase as markers for circulating tumor cells detection in patients with melanoma. Melanoma Res (2010) 20(4):293-302. doi:10.1097/CMR.0b013e32833906b6.
45. Kuzbicki L, Lange D, Chwirot BW. Cyclooxygenase-2 immunohistochemistry in human melanoma: differences between results obtained with different antibodies. Melanoma Res (2009) 19(5):294-300. doi:10.1097/CMR.0b013e32832e0bde.
46. Becker MR, Siegelin MD, Rompel R, Enk AH, Gaiser T. COX-2 expression in malignant melanoma: a novel prognostic marker? Melanoma Res (2009) 19(1):8-16. doi:10.1097/CMR.0b013e32831d7f52.
47. Nikkola J, Vihinen P, Vlaykova T, Hahka-Kemppinen M, Kahari VM, Pyrhonen S. High expression levels of collagenase-1 and stromelysin-1 correlate with shorter disease-free survival in human metastatic melanoma. Int J Cancer (2002) 97(4):432-8. doi:10.1002/ijc.1636.
48. Nikkola J, Vihinen P, Vuoristo MS, Kellokumpu-Lehtinen P, Kahari VM, Pyrhonen S. High serum levels of matrix metalloproteinase-9 and matrix metalloproteinase-1 are associated with rapid progression in patients with metastatic melanoma. Clin Cancer Res (2005) 11(14):5158-66. doi:10.1158/1078-0432.CCR-04-2478.
49. Rotte A, Martinka M, Li G. MMP2 expression is a prognostic marker for primary melanoma patients. Cell Oncol (Dordr) (2012) 35(3):207-16. doi:10.1007/s13402-012-0080-x.
50. Ugurel S, Rappl G, Tilgen W, Reinhold U. Increased serum concentration of angiogenic factors in malignant melanoma patients correlates with tumor progression and survival. J Clin Oncol (2001) 19(2):577-83.
51. Pelletier F, Bermont L, Puzenat E, Blanc D, Cairey-Remonnay S, Mougin C, et al. Circulating vascular endothelial growth factor in cutaneous malignant melanoma. Br J Dermatol (2005) 152(4):685-9. doi:10.1111/j.1365-2133.2005.06507.x.
52. Mouawad RSC, Soubrane C, Khayat D. Prognostic relevance of pretreatment soluble vascular endothelial growth factors (A, C, D) and their receptors (R1, R2 and R3) in advanced melanoma patients. J Clin Oncol (2007) 25(18s):8540.
53. Rangel J, Nosrati M, Torabian S, Shaikh L, Leong SP, Haqq C, et al. Osteopontin as a molecular prognostic marker for melanoma. Cancer (2008) 112(1):144-50. doi:10.1002/cncr.23147.
54. Alonso SR, Tracey L, Ortiz P, Perez-Gomez B, Palacios J, Pollan M, et al. A high-throughput study in melanoma identifies epithelial-mesenchymal transition as a major determinant of metastasis. Cancer Res (2007) 67(7):3450-60. doi:10.1158/0008-5472.CAN-06-3481.
55. Maier T, Laubender RP, Sturm RA, Klingenstein A, Korting HC, Ruzicka T, et al. Osteopontin expression in plasma of melanoma patients and in melanocytic tumours. J Eur Acad Dermatol Venereol (2012) 26(9):1084-91. doi:10.1111/j.1468-3083.2011.04210.x.
56. Brown ER, Doig T, Anderson N, Brenn T, Doherty V, Xu Y, et al. Association of galectin-3 expression with melanoma progression and prognosis. Eur J Cancer (2012) 48(6):865-74. doi:10.1016/j.ejca.2011.09.003.
57. Schmidt H, Johansen JS, Gehl J, Geertsen PF, Fode K, von der Maase H. Elevated serum level of YKL-40 is an independent prognostic factor for poor survival in patients with metastatic melanoma. Cancer (2006) 106(5):1130-9. doi:10.1002/cncr.21678.
58. Schmidt H, Johansen JS, Sjoegren P, Christensen IJ, Sorensen BS, Fode K, et al. Serum YKL-40 predicts relapse-free and overall survival in patients with American joint committee on cancer stage I and II melanoma. J Clin Oncol (2006) 24(5):798-804. doi:10.1200/JCO.2005.03.7960.
59. Diaz-Lagares A, Alegre E, Arroyo A, Gonzalez-Cao M, Zudaire ME, Viteri S, et al. Evaluation of multiple serum markers in advanced melanoma. Tumour Biol (2011) 32(6):1155-61. doi:10.1007/s13277-011-0218-x.
60. Essler M, Link A, Belloni B, Mirceva V, Souvatzoglou M, Thaler M, et al. Prognostic value of [18F]-fluoro-deoxy-glucose PET/CT, S100 or MIA for assessment of cancer-associated mortality in patients with high risk melanoma. PLoS One (2011) 6(9):e24632. doi:10.1371/journal.pone.0024632.
61. Sivan S, Suzan F, Rona O, Tamar H, Vivian B, Tamar P, et al. Serum CEACAM1 correlates with disease progression and survival in malignant melanoma patients. Clin Dev Immunol (2012) 2012:290536. doi:10.1155/2012/290536.
62. Bouwhuis MG, Suciu S, Kruit W, Sales F, Stoitchkov K, Patel P, et al. Prognostic value of serial blood S100B determinations in stage IIB-III melanoma patients: a corollary study to EORTC trial 18952. Eur J Cancer (2011) 47(3):361-8. doi:10.1016/j.ejca.2010.10.005.
63. Oberholzer PA, Urosevic M, Steinert HC, Dummer R. Baseline staging of melanoma with unknown primary site: the value of serum s100 protein and positron emission tomography. Dermatology (2008) 217(4):351-5. doi:10.1159/000155878.
64. Beyeler M, Waldispuhl S, Strobel K, Joller-Jemelka HI, Burg G, Dummer R. Detection of melanoma relapse: first comparative analysis on imaging techniques versus S100 protein. Dermatology (2006) 213(3):187-91. doi:10.1159/000095034.
65. Karagiannis P, Gilbert AE, Josephs DH, Ali N, Dodev T, Saul L, et al. IgG4 subclass antibodies impair antitumor immunity in melanoma. J Clin Invest (2013) 123(4):1457-74. doi:10.1172/JCI65579.
66. Sanmamed MF, Carranza-Rua O, Alfaro C, Onate C, Martin-Algarra S, Perez G, et al. Serum interleukin-8 reflects tumor burden and treatment response across malignancies of multiple tissue origins. Clin Cancer Res (2014) 20(22):5697-707. doi:10.1158/1078-0432.CCR-13-3203.
67. Solassol J, Du-Thanh A, Maudelonde T, Guillot B. Serum proteomic profiling reveals potential biomarkers for cutaneous malignant melanoma. Int J Biol Markers (2011) 26(2):82-7. doi:10.5301/JBM.2011.8344.
68. Vereecken P, Cornelis F, Van Baren N, Vandersleyen V, Baurain JF. A synopsis of serum biomarkers in cutaneous melanoma patients. Dermatol Res Pract (2012) 2012:260643. doi:10.1155/2012/260643.
69. Hofmann MA, Gussmann F, Fritsche A, Biesold S, Schicke B, Kuchler I, et al. Diagnostic value of melanoma inhibitory activity serum marker in the follow-up of patients with stage I or II cutaneous melanoma. Melanoma Res (2009) 19(1):17-23. doi:10.1097/CMR.0b013e32831bc78c.
70. Hofmann MA, Schicke B, Fritsch A, Biesold S, Gussmann F, Kuchler I, et al. Impact of lymph node metastases on serum level of melanoma inhibitory activity in stage III melanoma patients. J Dermatol (2011) 38(9):880-6. doi:10.1111/j.1346-8138.2011.01219.x.
71. Kluger HM, Hoyt K, Bacchiocchi A, Mayer T, Kirsch J, Kluger Y, et al. Plasma markers for identifying patients with metastatic melanoma. Clin Cancer Res (2011) 17(8):2417-25. doi:10.1158/1078-0432.CCR-10-2402.
72. Schmidt H, Sorensen BS, Fode K, Nexo E, von der Maase H. Tyrosinase messenger RNA in peripheral blood is related to poor survival in patients with metastatic melanoma following interleukin-2-based immunotherapy. Melanoma Res (2005) 15(5):409-16. doi:10.1097/00008390-200510000-00009.
73. Garbe C, Leiter U, Ellwanger U, Blaheta HJ, Meier F, Rassner G, et al. Diagnostic value and prognostic significance of protein S-100beta, melanoma-inhibitory activity, and tyrosinase/MART-1 reverse transcription-polymerase chain reaction in the follow-up of high-risk melanoma patients. Cancer (2003) 97(7):1737-45. doi:10.1002/cncr.11250.
74. Zhang H, Fu T, McGettigan S, Kumar S, Liu S, Speicher D, et al. IL-8 and cathepsin B as melanoma serum biomarkers. Int J Mol Sci (2011) 12(3):1505-18. doi:10.3390/ijms12031505.
75. Vihinen PP, Hilli J, Vuoristo MS, Syrjanen KJ, Kahari VM, Pyrhonen SO. Serum VEGF-C is associated with metastatic site in patients with malignant melanoma. Acta Oncol (2007) 46(5):678-84. doi:10.1080/02841860600965020.
76. McAllister SS, Gifford AM, Greiner AL, Kelleher SP, Saelzler MP, Ince TA, et al. Systemic endocrine instigation of indolent tumor growth requires osteopontin. Cell (2008) 133(6):994-1005. doi:10.1016/j.cell.2008.04.045.
77. Perrotta R, Bevelacqua Y, Malaguarnera G, Paladina I, Giordano M, Malaguarnera M. Serum markers of cutaneous melanoma. Front Biosci (2010) 2:1115-22. doi:10.2741/E170.
78. Volck B, Price PA, Johansen JS, Sorensen O, Benfield TL, Nielsen HJ, et al. YKL-40, a mammalian member of the chitinase family, is a matrix protein of specific granules in human neutrophils. Proc Assoc Am Physicians (1998) 110(4):351-60.
79. Schultz NA, Johansen JS. YKL-40-a protein in the field of translational medicine: a role as a biomarker in cancer patients? Cancers (Basel) (2010) 2(3):1453-91. doi:10.3390/cancers2031453.
80. Johansen JS, Jensen BV, Roslind A, Nielsen D, Price PA. Serum YKL-40, a new prognostic biomarker in cancer patients? Cancer Epidemiol Biomarkers Prev (2006) 15(2):194-202. doi:10.1158/1055-9965.EPI-05-0011.
81. Krogh M, Christensen IJ, Bouwhuis M, Johansen JS, Schmidt H, Hansson J, et al. Prognostic value of serum YKL-40 in stage IIB-III melanoma patients receiving adjuvant interferon therapy. J Clin Oncol (2010) 28(15s):8587.
82. Palmer SR, Erickson LA, Ichetovkin I, Knauer DJ, Markovic SN. Circulating serologic and molecular biomarkers in malignant melanoma. Mayo Clin Proc (2011) 86(10):981-90. doi:10.4065/mcp.2011.0287.
83. Juergensen A, Holzapfel U, Hein R, Stolz W, Buettner R, BosserhoffA. Comparison of two prognostic markers for malignant melanoma: MIA and S100 beta. Tumour Biol (2001) 22(1):54-8. doi:10.1159/000030147.
84. BosserhoffAK, Kuster H, Hein R. Elevated MIA levels in the serum of pregnant women and of children. Clin Exp Dermatol (2004) 29(6):628-9. doi:10.1111/j.1365-2230.2004.01623.x.
85. Davey GE, Murmann P, Hoechli M, Tanaka T, Heizmann CW. Calcium-dependent translocation of S100A11 requires tubulin filaments. Biochim Biophys Acta (2000) 1498(2-3):220-32. doi:10.1016/S0167-4889(00)00098-7.
86. Hsieh HL, Schafer BW, Cox JA, Heizmann CW. S100A13 and S100A6 exhibit distinct translocation pathways in endothelial cells. J Cell Sci (2002) 115(Pt 15):3149-58.
87. Petersson S, Shubbar E, Enerback L, Enerback C. Expression patterns of S100 proteins in melanocytes and melanocytic lesions. Melanoma Res (2009) 19(4):215-25. doi:10.1097/CMR.0b013e32832c6358.
88. KruijffS, Bastiaannet E, Kobold AC, van Ginkel RJ, Suurmeijer AJ, Hoekstra HJ. S-100B concentrations predict disease-free survival in stage III melanoma patients. Ann Surg Oncol (2009) 16(12):3455-62. doi:10.1245/s10434-009-0629-8.
89. Molina R, Navarro J, Filella X, Castel T, Ballesta AM. S-100 protein serum levels in patients with benign and malignant diseases: false-positive results related to liver and renal function. Tumour Biol (2002) 23(1):39-44. doi:10.1159/000048687.
90. Michetti F, Corvino V, Geloso MC, Lattanzi W, Bernardini C, Serpero L, et al. The S100B protein in biological fluids: more than a lifelong biomarker of brain distress. J Neurochem (2012) 120(5):644-59. doi:10.1111/j.1471-4159.2011.07612.x.
91. Tsoporis JN, Mohammadzadeh F, Parker TG. S100B: a multifunctional role in cardiovascular pathophysiology. Amino Acids (2011) 41(4):843-7. doi:10.1007/s00726-010-0527-1.
92. Meyer S, Vogt T, Landthaler M, Berand A, Reichle A, Bataille F, et al. Cyclooxygenase 2 (COX2) and peroxisome proliferator-activated receptor gamma (PPARG) are stage-dependent prognostic markers of malignant melanoma. PPAR Res (2009) 2009:848645. doi:10.1155/2010/848645.
93. BosserhoffAK. Novel biomarkers in malignant melanoma. Clin Chim Acta (2006) 367(1-2):28-35. doi:10.1016/j.cca.2005.10.029.
94. Buljan M, Situm M, Tomas D, Milosevic M, Kruslin B. Prognostic value of galectin-3 in primary cutaneous melanoma. J Eur Acad Dermatol Venereol (2011) 25(10):1174-81. doi:10.1111/j.1468-3083.2010.03943.x.
95. Stamenkovic I. Extracellular matrix remodelling: the role of matrix metalloproteinases. J Pathol (2003) 200(4):448-64. doi:10.1002/path.1400.
96. Stamenkovic I. Matrix metalloproteinases in tumor invasion and metastasis. Semin Cancer Biol (2000) 10(6):415-33. doi:10.1006/scbi.2000.0379.
97. Sapoznik S, Ortenberg R, Schachter J, Markel G. CEACAM1 in malignant melanoma: a diagnostic and therapeutic target. Curr Top Med Chem (2012) 12(1):3-10. doi:10.2174/156802612798919259.
98. Thies A, Moll I, Berger J, Wagener C, Brummer J, Schulze HJ, et al. CEACAM1 expression in cutaneous malignant melanoma predicts the development of metastatic disease. J Clin Oncol (2002) 20(10):2530-6. doi:10.1200/JCO.2002.05.033.
99. Ebrahimnejad A, Streichert T, Nollau P, Horst AK, Wagener C, Bamberger AM, et al. CEACAM1 enhances invasion and migration of melanocytic and melanoma cells. Am J Pathol (2004) 165(5):1781-7. doi:10.1016/S0002-9440(10)63433-5.
100. Franzke A, Probst-Kepper M, Buer J, Duensing S, Hoffmann R, Wittke F, et al. Elevated pretreatment serum levels of soluble vascular cell adhesion molecule 1 and lactate dehydrogenase as predictors of survival in cutaneous metastatic malignant melanoma. Br J Cancer (1998) 78(1):40-5. doi:10.1038/bjc.1998.439.
101. Hirai S, Kageshita T, Kimura T, Tsujisaki M, Imai K, Wakamatsu K, et al. Serum levels of sICAM-1 and 5-S-cysteinyldopa as markers of melanoma progression. Melanoma Res (1997) 7(1):58-62. doi:10.1097/00008390-199702000-00009.
102. Ross AH, Cossu G, Herlyn M, Bell JR, Steplewski Z, Koprowski H. Isolation and chemical characterization of a melanoma-associated proteoglycan antigen. Arch Biochem Biophys (1983) 225(1):370-83. doi:10.1016/0003-9861(83)90042-5.
103. Campoli M, Ferrone S, Wang X. Functional and clinical relevance of chondroitin sulfate proteoglycan 4. Adv Cancer Res (2010) 109:73-121. doi:10.1016/B978-0-12-380890-5.00003-X.
104. Vergilis IJ, Szarek M, Ferrone S, Reynolds SR. Presence and prognostic significance of melanoma-associated antigens CYT-MAA and HMW-MAA in serum of patients with melanoma. J Invest Dermatol (2005) 125(3):526-31. doi:10.1111/j.0022-202X.2005.23798.x.
105. Reynolds SR, Vergilis IJ, Szarek M, Ferrone S, Bystryn JC. Cytoplasmic melanoma-associated antigen (CYT-MAA) serum level in patients with melanoma: a potential marker of response to immunotherapy? Int J Cancer (2006) 119(1):157-61. doi:10.1002/ijc.21820.
106. Tan TT, Coussens LM. Humoral immunity, inflammation and cancer. Curr Opin Immunol (2007) 19(2):209-16. doi:10.1016/j.coi.2007.01.001.
107. Whiteside TL. Immune responses to cancer: are they potential biomarkers of prognosis? Front Oncol (2013) 3:107. doi:10.3389/fonc.2013.00107.
108. Massi D, Brusa D, Merelli B, Ciano M, Audrito V, Serra S, et al. PD-L1 marks a subset of melanomas with a shorter overall survival and distinct genetic and morphological characteristics. Ann Oncol (2014) 25(12):2433-42. doi:10.1093/annonc/mdu452.
109. Ji RR, Chasalow SD, Wang L, Hamid O, Schmidt H, Cogswell J, et al. An immune-active tumor microenvironment favors clinical response to ipilimumab. Cancer Immunol Immunother (2012) 61(7):1019-31. doi:10.1007/s00262-011-1172-6.
110. Galon J, Costes A, Sanchez-Cabo F, Kirilovsky A, Mlecnik B, Lagorce-Pages C, et al. Type, density, and location of immune cells within human colorectal tumors predict clinical outcome. Science (2006) 313(5795):1960-4. doi:10.1126/science.1129139.
111. Pages F, Berger A, Camus M, Sanchez-Cabo F, Costes A, Molidor R, et al. Effector memory T cells, early metastasis, and survival in colorectal cancer. N Engl J Med (2005) 353(25):2654-66. doi:10.1056/NEJMoa051424.
112. Whiteside TL, Mandapathil M, Szczepanski M, Szajnik M. Mechanisms of tumor escape from the immune system: adenosine-producing Treg, exosomes and tumor-associated TLRs. Bull Cancer (2011) 98(2):E25-31. doi:10.1684/bdc.2010.1294.
113. Lanca T, Silva-Santos B. The split nature of tumor-infiltrating leukocytes: implications for cancer surveillance and immunotherapy. Oncoimmunology (2012) 1(5):717-25. doi:10.4161/onci.20068.
114. Meyer C, Cagnon L, Costa-Nunes CM, Baumgaertner P, Montandon N, Leyvraz L, et al. Frequencies of circulating MDSC correlate with clinical outcome of melanoma patients treated with ipilimumab. Cancer Immunol Immunother (2014) 63(3):247-57. doi:10.1007/s00262-013-1508-5.
115. Nielsen JS, Sahota RA, Milne K, Kost SE, Nesslinger NJ, Watson PH, et al. CD20+ tumor-infiltrating lymphocytes have an atypical CD27-memory phenotype and together with CD8+ T cells promote favorable prognosis in ovarian cancer. Clin Cancer Res (2012) 18(12):3281-92. doi:10.1158/1078-0432.CCR-12-0234.
116. Cenci S, Sitia R. Managing and exploiting stress in the antibody factory. FEBS Lett (2007) 581(19):3652-7. doi:10.1016/j.febslet.2007.04.031.
117. Forster I, Rajewsky K. The bulk of the peripheral B-cell pool in mice is stable and not rapidly renewed from the bone marrow. Proc Natl Acad Sci USA (1990) 87(12):4781-4. doi:10.1073/pnas.87.12.4781.
118. Cooperman J, Neely R, Teachey DT, Grupp S, Choi JK. Cell division rates of primary human precursor B cells in culture reflect in vivo rates. Stem Cells (2004) 22(6):1111-20. doi:10.1634/stemcells.22-6-1111.
119. Schmidt M, Hellwig B, Hammad S, Othman A, Lohr M, Chen Z, et al. A comprehensive analysis of human gene expression profiles identifies stromal immunoglobulin kappa C as a compatible prognostic marker in human solid tumors. Clin Cancer Res (2012) 18(9):2695-703. doi:10.1158/1078-0432.CCR-11-2210.
120. Schmidt M, Bohm D, von Torne C, Steiner E, Puhl A, Pilch H, et al. The humoral immune system has a key prognostic impact in node-negative breast cancer. Cancer Res (2008) 68(13):5405-13. doi:10.1158/0008-5472.CAN-07-5206.
121. Gilbert AE, Karagiannis P, Dodev T, Koers A, Lacy K, Josephs DH, et al. Monitoring the systemic human memory B cell compartment of melanoma patients for anti-tumor IgG antibodies. PLoS One (2011) 6(4):e19330. doi:10.1371/journal.pone.0019330.
122. Carpenter EL, Mick R, Rech AJ, Beatty GL, Colligon TA, Rosenfeld MR, et al. Collapse of the CD27+ B-cell compartment associated with systemic plasmacytosis in patients with advanced melanoma and other cancers. Clin Cancer Res (2009) 15(13):4277-87. doi:10.1158/1078-0432.CCR-09-0537.
123. Daveau M, Pavie-Fischer J, Rivat L, Rivat C, Ropartz C, Peter HH, et al. IgG4 subclass in malignant melanoma. J Natl Cancer Inst (1977) 58(2):189-92.
124. Harada K, Shimoda S, Kimura Y, Sato Y, Ikeda H, Igarashi S, et al. Significance of immunoglobulin G4 (IgG4)-positive cells in extrahepatic cholangiocarcinoma: molecular mechanism of IgG4 reaction in cancer tissue. Hepatology (2012) 56(1):157-64. doi:10.1002/hep.25627.
125. Jeannin P, Lecoanet S, Delneste Y, Gauchat JF, Bonnefoy JY. IgE versus IgG4 production can be differentially regulated by IL-10. J Immunol (1998) 160(7):3555-61.
126. Satoguina JS, Weyand E, Larbi J, Hoerauf A. T regulatory-1 cells induce IgG4 production by B cells: role of IL-10. J Immunol (2005) 174(8):4718-26. doi:10.4049/jimmunol.174.8.4718.
127. Stone JH, Zen Y, Deshpande V. IgG4-related disease. N Engl J Med (2012) 366(6):539-51. doi:10.1056/NEJMra1104650.
128. Restrepo L, Stafford P, Johnston SA. Feasibility of an early Alzheimer's disease immunosignature diagnostic test. J Neuroimmunol (2013) 254(1-2):154-60. doi:10.1016/j.jneuroim.2012.09.014.
129. Hughes AK, Cichacz Z, Scheck A, Coons SW, Johnston SA, Stafford P. Immunosignaturing can detect products from molecular markers in brain cancer. PLoS One (2012) 7(7):e40201. doi:10.1371/journal.pone.0040201.
130. Tsoka S, Ainali C, Karagiannis P, Josephs DH, Saul L, Nestle FO, et al. Toward prediction of immune mechanisms and design of immunotherapies in melanoma. Crit Rev Biomed Eng (2012) 40(4):279-94. doi:10.1615/CritRevBiomedEng.v40.i4.40.